HPAPI Outsourcing Drivers
Source: ISR Reports
In Q12022, ISR surveyed 100 sponsors who outsource highly potent small molecule drug substance manufacturing and asked them why their companies use CDMOs for the work. The data show the bulk of respondents are augmenting the supply they make in-house (42%). Another 27 percent of respondents (27%) have small molecule manufacturing capabilities, but do not have segregated manufacturing capabilities and one-quarter have no manufacturing capacity / outsource 100% of manufacturing. To learn more, follow the link to ISR’s Highly Potent Manufacturing Market Outlook report preview.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.
Subscribe to Outsourced Pharma
X
Subscribe to Outsourced Pharma
ISR Reports
This website uses cookies to ensure you get the best experience on our website. Learn more